285 related articles for article (PubMed ID: 7718484)
21. Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells.
Franklin CC; Kraft AS
Oncogene; 1995 Dec; 11(11):2365-74. PubMed ID: 8570188
[TBL] [Abstract][Full Text] [Related]
22. Rac1 and extracellularly regulated kinase activation are sufficient for E1A-dependent cooperative transformation of primary epithelial cells, but progression can only be modulated by E1A or Rac1.
Fischer RS; Zheng Y; Quinlan MP
Cell Growth Differ; 1998 Mar; 9(3):209-21. PubMed ID: 9543387
[TBL] [Abstract][Full Text] [Related]
23. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
24. The role of v-mos in transformation, oncogenicity, and metastatic potential of mink lung cells.
Gao CL; Wang LC; Vass WC; Seth A; Chang KS
Oncogene; 1988 Sep; 3(3):267-73. PubMed ID: 2849740
[TBL] [Abstract][Full Text] [Related]
25. Activation of the Xenopus oocyte mitogen-activated protein kinase pathway by Mos is independent of Raf.
Shibuya EK; Morris J; Rapp UR; Ruderman JV
Cell Growth Differ; 1996 Feb; 7(2):235-41. PubMed ID: 8822207
[TBL] [Abstract][Full Text] [Related]
26. Evidence for interaction between v-Mos and a p34cdc2 isoform, p35cdk.
Bai W; Singh B; Yang Y; Arlinghaus RB
Oncogene; 1992 Sep; 7(9):1757-63. PubMed ID: 1323818
[TBL] [Abstract][Full Text] [Related]
27. Cell cycle-mediated structural and functional alteration of P85gag-mos protein kinase activity.
Liu JX; Singh B; Wlodek D; Arlinghaus RB
Oncogene; 1990 Feb; 5(2):171-8. PubMed ID: 2138725
[TBL] [Abstract][Full Text] [Related]
28. A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation.
Urich M; Senften M; Shaw PE; Ballmer-Hofer K
Oncogene; 1997 Mar; 14(10):1235-41. PubMed ID: 9121774
[TBL] [Abstract][Full Text] [Related]
29. v-Ras and v-Raf block differentiation of transformable C3H10T1/2-derived preadipocytes at lower levels than required for neoplastic transformation.
Raptis L; Brownell HL; Lu Y; Preston T; Narsimhan RP; Anderson S; Schaefer E; Haliotis T
Exp Cell Res; 1997 Aug; 235(1):188-97. PubMed ID: 9281368
[TBL] [Abstract][Full Text] [Related]
30. Association of v-Mos with soluble vimentin in vitro and in transformed cells.
Bai W; Arlinghaus RB; Singh B
Oncogene; 1993 Aug; 8(8):2207-12. PubMed ID: 8336943
[TBL] [Abstract][Full Text] [Related]
31. Similarities between somatic cells overexpressing the mos oncogene and oocytes during meiotic interphase.
Fukasawa K; Murakami MS; Blair DG; Kuriyama R; Hunt T; Fischinger P; Vande Woude GF
Cell Growth Differ; 1994 Oct; 5(10):1093-103. PubMed ID: 7848911
[TBL] [Abstract][Full Text] [Related]
32. A threshold effect in the induction of tumorigenicity of an established human cell line by v-mos.
O'Hara BM; Blair DG
Oncogene; 1988 Sep; 3(3):295-9. PubMed ID: 2974527
[TBL] [Abstract][Full Text] [Related]
33. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
34. A common cellular pathway for v-mos and v-Ki-ras is not required for v-Ki-ras-induced tumorigenicity in a nonmalignant, v-mos-expressing revertant cell.
Gerfaux J; Sergiescu D; Hamelin R; Joret AM; Lallemand C
Mol Carcinog; 1990; 3(2):103-13. PubMed ID: 2161237
[TBL] [Abstract][Full Text] [Related]
35. Generation of macrophage cell line from fresh bone marrow cells with a myc/raf recombinant retrovirus.
Blasi E; Radzioch D; Merletti L; Varesio L
Cancer Biochem Biophys; 1989 Oct; 10(4):303-17. PubMed ID: 2695237
[TBL] [Abstract][Full Text] [Related]
36. C127 cells resistant to transformation by tyrosine protein kinase oncogenes.
Cuadrado A; Talbot N; Barbacid M
Cell Growth Differ; 1990 Jan; 1(1):9-15. PubMed ID: 2150330
[TBL] [Abstract][Full Text] [Related]
37. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice.
Kurie JM; Morse HC; Principato MA; Wax JS; Troppmair J; Rapp UR; Potter M; Mushinski JF
Oncogene; 1990 Apr; 5(4):577-82. PubMed ID: 2183159
[TBL] [Abstract][Full Text] [Related]
38. Functions of the mos oncogene family and associated gene products.
Bold RJ; Hannink M; Donoghue DJ
Cancer Surv; 1986; 5(2):243-55. PubMed ID: 2946405
[TBL] [Abstract][Full Text] [Related]
39. Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos.
Basu A; Lazo JS
Cancer Res; 1991 Feb; 51(3):893-6. PubMed ID: 1824827
[TBL] [Abstract][Full Text] [Related]
40. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability.
Fukasawa K; Vande Woude GF
Mol Cell Biol; 1997 Jan; 17(1):506-18. PubMed ID: 8972231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
